Chronic myeloid leukemia: Practical issues in diagnosis, treatment and follow-up

Buyukasik Y., Haznedaroglu I. C., İLHAN .

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.20, sa.2 SUPPL., ss.1-12, 2010 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 20 Sayı: 2 SUPPL.
  • Basım Tarihi: 2010
  • Dergi Adı: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1-12
  • Anahtar Kelimeler: BCR-ABL, Chronic myeloid leukemia, Dasatinib, Imatinib, Nilotinib, Philadelphia chromosome
  • Lokman Hekim Üniversitesi Adresli: Evet

Özet

Chronic myeloid leukemia (CML) is sometimes mentioned as the disease of "firsts". 1) It is the first disease where the term "leukemia" was used. 2) It is the first neoplastic disorder which was found to be associated with a recurrent chromosomal abnormality. 3) It is the first disease where targeted therapy against a fusion protein was used. Entrance of BCR-ABL tyrosine kinase inhibitors, first imatinib and then dasatinib and nilotinib, into clinical practice within the last decade has fundamentally changed both treatment and follow-up of CML. In this review, practical points about CML have been summarized, with a special emphasis to treatment and follow-up.